Dose intensity and efficacy of the combination of everolimus and exemestane (EVE/EXE) in a real-world population of hormone receptor-positive (ER+/PgR+), HER2-negative advanced breast cancer (ABC) patients: a multicenter Italian experience

Publication | Closed Access

DOI

Citations

References

2017

Year

Mariangela Ciccarese, Alessandra Fabi, Luca Moscetti, Marina Elena Cazzaniga, Luciana Petrucelli, R. Forcignanò, Laura Isabella Lupo, Elisabetta De Matteis, Vincenzo Emanuele Chiurì, Giuseppe Cairo,

Breast Cancer Research and Treatment

Real-world PopulationBreast OncologyMedicinePharmacologyDose IntensityBreast CancerPharmacotherapyCancer TreatmentOncologyRadiation OncologyEndocrine-related Cancer